ANGPTL3 as a target for treating lipid disorders in type 2 diabetes patients

• Published in: Lipids in health and disease Vol. 23; no. 1; pp. 356 - 9
• Main Authors: Chen, Jingfei, Luo, Qin, Yi, Yanfeng, Wang, Jiangang, Chen, Pengfei, Luo, Fei, Fang, Zhenfei
• Format: Journal Article
• Language: English
• Published: BioMed Central Ltd 01.11.2024; BMC
• Subjects: Angiopoietin-like protein 3; Antilipemic agents; Blood lipids; Cardiovascular disease; Cardiovascular diseases; Cholesterol; Diabetic dyslipidemia; Diabetics; Health aspects; Hyperglycemia; Insulin; Insulin resistance; Lipoprotein lipase; Liver; Low density lipoproteins; Triglycerides; Type 2 diabetes; Type 2 diabetes mellitus
• ISSN: 1476-511X; 1476-511X
• DOI: 10.1186/s12944-024-02352-1

Type 2 diabetes mellitus (T2DM) is a globally prevalent metabolic disorder, and cardiovascular disease (CVD) is a significant cause of mortality and morbidity in diabetic individuals. In addition to hyperglycemia, lipid abnormalities associated with T2DM play a crucial role in the development of CVD complications. Diabetic dyslipidemia is characterized by elevated levels of triglyceride (TG)-rich lipoproteins and small dense low-density lipoprotein (LDL) particles, reduced high-density lipoprotein (HDL) cholesterol, and impaired HDL function. Angiopoietin protein-like 3 (ANGPTL3) is a liver-derived protein that plays a crucial role in regulating plasma lipoprotein metabolism by inhibiting lipoprotein lipase and influencing lipid levels. Inhibiting ANGPTL3 has shown promising effects in promoting HDL-mediated cholesterol reverse transport and reducing the levels of TG-rich lipoproteins and LDL cholesterol. Here, we explore the potential of ANGPTL3 as a therapeutic target for lipid management in T2DM patients. Keywords: Type 2 diabetes mellitus, Diabetic dyslipidemia, Insulin resistance, Cardiovascular disease, Angiopoietin-like protein 3